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Background: Surgical site infection (SSI) is a major source of morbidity after infrainguinal lower extremity bypass (LEB).
This study examines processes of care associated with in-hospital SSI after LEB and identiﬁes factors that could poten-
tially be modiﬁed to improve outcomes.
Methods: The Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) registry (2003 to 2012) was queried to
identify in-hospital SSI after 7908 consecutive LEB procedures performed by 365 surgeons at 91 academic and com-
munity hospitals in 45 states. Variables associated with SSI were identiﬁed using multivariable logistic regression and
hierarchical clustering. Expected and observed SSI rates were calculated for each hospital.
Results: The overall in-hospital SSI rate after LEB was 4.8%. Univariate analysis showed that obesity, dialysis, tissue loss,
preoperative ankle-brachial index <0.35, distal target, vein graft conduit, continuous incision for vein harvest, trans-
fusion >2 units of packed red blood cells, procedure time >220 minutes, and estimated blood loss >100 mL were
associated with higher SSI rates, whereas chlorhexidine (compared with iodine) skin preparation was protective.
Multivariable analysis showed independent predictors of SSI included ankle-brachial index <0.35 (odds ratio [OR], 1.53;
95% conﬁdence interval [CI], 1.03-2.30, P < .04), transfusion >2 units (OR, 3.30; 95% CI, 2.17-5.02; P < .001), and
procedure time >220 minutes (OR, 2.11; 95% CI, 1.05-4.23; P < .04). Chlorhexidine was protective against SSI (OR,
0.53; 95% CI, 0.35-0.79; P[ .002). Stratiﬁed analyses based on the presence of tissue loss yielded similar results. Across
VQI hospitals, observed SSI rates ranged from 0% to 30%, whereas expected SSI rates adjusted by the four independent
predictors ranged from 0% to 7.2%.
Conclusions: In-hospital SSI after LEB varies substantially across VQI hospitals. Three modiﬁable processes of care
(transfusion rate, procedure time, and type of skin preparation) were identiﬁed and may be used by hospitals to reduce
SSI rates. This study demonstrates the value of the SVS VQI detailed shared clinical registry to identify improvement
opportunities directly pertinent to providers that are not available in typical administrative data sets. (J Vasc Surg
2014;60:1238-46.)Surgical site infection (SSI) is a well-described compli-
cation in vascular surgery and is commonly observed
among patients treated with infrainguinal lower extremity
bypass (LEB). This complication poses a signiﬁcant
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8pain, cardiovascular complications, return to the operating
room, increased hospital length of stay, increased resource
use, and readmission.1,2 Furthermore, SSI is a potential
reason cited for performing endovascular revascularization
in lieu of LEB in patients with symptomatic peripheral arte-
rial disease.3 Certain infectious complications (urinary tract
infections and catheter-based bloodstream infections) have
already become targeted as performance measures with sig-
niﬁcant ﬁnancial reimbursement ramiﬁcations for treating
surgeons and hospitals.4,5 The possibility that SSI could
be added to this list of potentially preventable events in
the future is conceivable.
The published incidence of SSI after LEB has varied,
with different rates reported based on the evaluated data
set. A recent study using data from the American College
of Surgeons National Surgical Quality Improvement Pro-
gram (ACS-NSQIP) revealed a 30-day SSI rate of
11.1%.6 The Project of Ex-Vivo Vein Graft Engineering
via Transfection (PREVENT III) trial cited an overall
30-day wound complication rate of 39.0% and wound
infection rate of 20.2% among 1404 patients undergoing
LEB.7 Furthermore, the Bypass vs Angioplasty in Severe
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15.6% in-hospital and 30-day wound infection rate,
respectively.3
A number of clinical variables have been described as
being directly related to the incidence of SSI. Reported
patient-related factors include female gender,6,8 oral anti-
coagulants,8 advanced age,1 obesity,6,9 dialysis depen-
dence,10 and diabetes.11 More recently, perioperative
variables, including blood transfusion12,13 and operative
duration, have been linked to SSI.6.14 Although these vari-
ables have been studied in combined analyses of various
vascular operations, including LEB, a dedicated evaluation
of their relationship to SSI after LEB has not yet been
undertaken. In addition, the few studies that have evalu-
ated SSI after LEB have had inherent database limitations.
The purpose of our study was to use the Society for
Vascular Surgery (SVS) Vascular Quality Initiative (VQI)
registry to determine risk factors for in-hospital SSI after
LEB. Furthermore, we sought to analyze the variation of
SSI across VQI centers as well as the variation in modiﬁable
risk factors that could be used in a quality improvement
initiative to decrease SSI rates.
METHODS
Study design. This was a retrospective observational
study of the VQI registry supported by the SVS Patient
Safety Organization (www.vascularqualityinitiative.org).15
The VQI is a collaboration of regional quality groups
modeled after the Vascular Study Group of New England
(VSGNE) (www.vsgne.org), which has demonstrated the
ability to use aggregated data to recognize patterns of
outcomes and their associated causes since its development
in 2002.16 Hospital personnel and surgeons enter patient
demographic and clinical variables, along with procedural
and postoperative variables, into a Web-based data collec-
tion platform. Variables associated with SSI were identiﬁed
using multivariable logistic regression and hierarchical
clustering. Expected and observed SSI rates were calculated
for each hospital. The Institutional Review Board at Bos-
ton University School of Medicine approved the use of the
deidentiﬁed data for this study, and patient informed
consent was waived.
Patient population. A total of 7908 LEBs were per-
formed in the VQI by 365 surgeons at 91 academic and
community hospitals in 45 states during the study interval
from January 2003 through June 2012.
Inclusion/exclusion criteria. We included all patients
who underwent elective, urgent, or emergency open
infrainguinal revascularization procedures for claudication,
critical limb ischemia (rest pain/tissue loss), and acute
ischemia. We excluded LEBs performed for infrainguinal
aneurysms and for revisions of previous bypasses. Included
were all LEBs with an inﬂow origin from the common
femoral artery, profunda femoris artery, superﬁcial femoral
artery, and the above-knee or below-knee popliteal artery.
Patients undergoing concomitant suprainguinal bypass
were excluded. Outﬂow target arteries included the above-
knee and below-knee popliteal arteries, as well as distaltargets deﬁned as tibial and pedal vessels. Conduits
included autogenous leg vein (in situ, reversed, and non-
reversed), autogenous arm vein, composite vein, and
prosthetic grafts. The analysis excluded 23 LEB procedures
because data recording SSI were incomplete.
Outcome and variable deﬁnitions. Our analysis
reviewed patient demographics, pre-existing medical
comorbidities, and operative details. More than 100 vari-
ables were collected prospectively for each procedure and
recorded in the VQI database. The deﬁnitions of medical
comorbidities and procedure details within VQI, as
modeled after VSGNE, have been previously described.16
The main outcome measure of SSI was deﬁned in the
VQI database as clinical evidence of infection in the sur-
gical incision that was culture-positive or required antibi-
otic treatment, or both, during the index hospitalization.
Wound breakdown and dehiscence were not included
speciﬁcally in the VQI deﬁnition unless infection was pre-
sent as deﬁned above.
Statistical analysis. Univariate comparison of SSI and
patient, preoperative, and intraoperative variables was per-
formed. Variables were considered signiﬁcantly associated
with SSI at a P of <.10 and were entered into a multivari-
able model using backwards stepwise logistic regression,
which generated odds ratios (ORs) for each signiﬁcant pre-
dictor of SSI. The expected SSI rate was calculated from
the model, and the observed and the expected SSI rates
were calculated for each hospital. Variation of overall SSI
rates and the rates for individual predictors of SSI was eval-
uated across the VQI centers. The c2 statistic was per-
formed to determine if expected SSI was signiﬁcantly
different (P < .05) from observed SSI for each hospital.
Statistical analysis was performed using STATA 8.0
software (StataCorp LP, College Station, Tex).RESULTS
Study population. There were 7034 patients who un-
derwent 7908 LEB procedures between January 2003 and
June 2012. Across 45 states, 365 surgeons from 91 aca-
demic and community medical centers contributed be-
tween one and 486 LEB procedures per surgeon (median
number of 10 LEB per surgeon; interquartile range
[IQR], 3-21). Between one and 1360 procedures were
performed per medical center. The median number of pro-
cedures by center was 38 (IQR, 9-84), and 52 of 91 cen-
ters contributed $30 or more LEB procedures. Table I
summarizes the basic demographic data of the patient
population.
Procedural details. The indication for LEB was
recorded as critical limb ischemia in 69% (37% tissue loss,
22% rest pain, and 10% acute ischemia), claudication in
26%, and asymptomatic in 5% of procedures. Elective pro-
cedures accounted for 76%, whereas 24% were urgent or
emergencies. The preoperative ankle-brachial index (ABI)
was recorded in 69% of the cohort and was <0.35 in 28%
of these patients. Preoperative antibiotics were recorded as
given 94% of the time.
Table I. Demographics of the patient population
Variable No. Percentage
Patient procedures 7885 100
Make gender 5424 69
Age, years
<40 77 1.0
40 to 49 447 5.7
50 to 59 1615 20
60 to 69 2378 30
70 to 79 2176 28
80 to 89 1080 14
>89 112 1.4
Race
Black or African American 626 7.9
Caucasian 7029 89
Unknown/other 228 3.0
BMI
Underweight 389 5.1
Normal weight 2560 33
Overweight 2516 33
Obese (BMI $30 kg/m2) 2220 29.1
Smoking
Never 1238 16
Prior (>1 year) 3283 42
Current (#1 year) 3347 43
Hypertension ($140/90 mm Hg or history) 6767 86
Diabetes
None 4106 52
Diet 413 5.2
Oral medications 1450 18
Insulin 1906 24
CHF
None 6690 85
Asymptomatic, history of CHF 704 8.9
Mild 371 4.7
Severe 110 1.4
COPD
No 5853 76
Not treated 836 11
On medications 1014 13
Dialysis
No 7360 93
Functioning transplant 69 0.9
On dialysis 448 5.7
Pre-op living status at home 7592 97
Pre-op hemoglobin >9 mg/dL 5335 95
Hemoglobin A1c #8 mg/dL 1095 77
Indication
Asymptomatic 400 5.1
Claudication 2027 26
Rest rain 1694 22
Tissue loss 2929 37
Acute ischemia 757 10
Ambulation 5994 76
Pre-op ABI $0.35 3898 72
Urgency
Elective 5991 76
Urgent/emergency 1885 24
Skin preparation
Chlorhexidine 1104 27
Chlorhexidine þ alcohol 1529 37
Iodine 509 12
Iodine þ alcohol 687 17
Chlorhexidine þ iodine 114 2.8
Alcohol 30 0.7
All 3 134 3.3
Pre-op antibiotics 4844 94
(Continued)
Table I. Continued.
Variable No. Percentage
Graft origin
External iliac 206 2.6
CFA 5180 66
SFA 1460 19
Profunda femoral 255 3.2
Above-knee popliteal 378 4.8
Below-knee popliteal 358 4.6
Tibial 22 0.3
Graft recipient
CFA/SFA/profunda 404 5.1
Above-knee popliteal 1830 23
Below-knee popliteal 2625 33
Tibial 2405 30.4
Dorsalis pedis/posterior tibial 535 6.8
Tarsal/plantar 59 0.8
Vein grafts
None 2527 32
Great saphenous vein
Reversed 2008 26
In situ 1843 23
Nonreversed transposed 919 12
Small saphenous vein 60 0.8
Cephalic/basilic vein 177 2.2
Composite vein 313 4.0
Conduit type
Prosthetic 2373 30
Vein graft 5423 70
Groin incision
None 612 15
Vertical 2788 69
Horizontal 641 16
Vein harvest incision
Continuous 1373 54
Skip/endoscopic 1187 46
Subcutaneous vein graft location 1373 54
No endarterectomy 4253 98
No transfusion 7194 91
Procedure time, minutes
#160 1002 25
161 to 220 1069 26
221 to 290 964 24
$291 1025 25
Estimated blood loss, mL
#100 1787 32
101 to 200 1531 27
201 to 300 906 16
$301 1376 25
No completion study 4081 52
Length of stay, days
#3 2441 31
4 or 5 1637 21
6 to 9 1795 23
$10 2011 26
ABI, Ankle-brachial index; BMI, body mass index; CFA, common femoral
artery; CHF, congestive heart failure; COPD, chronic obstructive pulmo-
nary disease; SFA, superﬁcial femoral artery.
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and data were missing for 10% of eligible procedures after
that time. Chlorhexidine (with or without alcohol) was
used in 64% of procedures, whereas iodine (with or without
alcohol) was used in 29%. The other three skin preparation
options of alcohol (0.7%), chlorhexidine with iodine
Table II. Surgical site infection (SSI) rates by univariate
analysis of the cohort
Variable SSI rate, % OR P
Gender
Female 5.4 1.21 .082
Male 4.5
BMI
Obese (BMI $30 kg/m2) 5.6 1.35 .009
Not obese 4.3
Diabetes
Yes 5.0 1.12 .277
No 4.5
Dialysis
Yes 6.7 1.48 .046
No 4.6
Pre-op hemoglobin, mg/dL
#9 5.4 1.22 .456
>9 4.5
Indication
Tissue loss 5.7 1.38 .003
No tissue loss 4.2
Acute ischemia
Yes 6.2 1.37 .051
No 4.6
Pre-op ABI
<0.35 6.1 1.29 .049
$0.35 4.8
Urgency
Urgent/emergency 5.6 1.25 .063
Elective 4.5
Skin preparation
Chlorhexidine or w/alcohol 3.5 0.62 .003
Iodine or w/alcohol 5.6
Pre-op antibiotics
Yes 4.5 0.72 .182
No 6.1
Graft recipient
Distal target 5.1 1.3 .042
Other 3.9
Conduit type
Prosthetic 4.3 1.28 .037
Vein 5.4
Groin incision
Vertical 4.8 1.56 .070
Horizontal 3.1
Vein harvest incision
Continuous 6.1 2.28 <.001
Skip/endoscopic 2.8
Transfusion
Yes 10.7 2.74 <.001
No 4.2
Procedure time, minutes
#160 2.4
161 to 220 3.2 1.34 .281
221 to 290 5.2 2.18 .002
$291 6.4 2.8 <.001
Estimated blood loss, mL
#100 2.5
101 to 200 3.7 1.53 .036
201 to 300 5.9 2.46 <.001
$301 7.4 3.17 <.001
Completion study
Duplex or angiogram 5.9 1.63 <.001
No 3.7
Length of stay, days
#3 1.1
(Continued)
Table II. Continued.
Variable SSI rate, % OR P
4 or 5 3.4 3.22 <.001
6 to 9 5.4 5.31 <.001
$10 9.9 10.14 <.001
ABI, Ankle-brachial index; BMI, body mass index; OR, odds ratio.
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were excluded from the analysis due to low numbers.
Procedure timewas also added as a variable in July 2010,
and data were missing for 5% of eligible procedures after that
time. Quartiles (Q) were deﬁned as #160 minutes, 161 to
220 minutes, 221 to 290 minutes, and $291 minutes.
Transfusion of >2 units of packed red blood cells
(pRBCs) was used in 9% of procedures (data not recorded
in 6% of patients). Estimated blood loss was divided into
four groups: #100 mL (32% of LEBs), 101 to 200 mL
(27%), 201 to 300 mL (16%), and $301 mL (25%).
Missing data were not imputed; thus, a procedure that
was missing data was not entered into the ﬁnal models.
Outcome of SSI. SSI was noted in 376 of 7885 LEB
procedures (4.8%). Univariate analysis of the cohort
(Table II) showed variables signiﬁcantly associated with
SSI included obesity (body mass index $30 kg/m2; 5.6%
vs 4.3%), dialysis dependence (6.7% vs 4.6%), tissue loss
indication (5.7% vs 4.2%), preoperative ABI <0.35 (6.1%
vs 4.8%), distal target (5.1% vs 3.9%), use of vein graft
conduits (5.4% vs 4.3%), continuous incision for vein har-
vest (6.1% vs 2.8%), and transfusion >2 units (10.7% vs
4.2%). Analysis of procedure time revealed that increasing
the duration of an operation led to a stepwise and signiﬁ-
cant increase in risk of SSI (6.4% vs 5.1% vs 3.2% vs 2.4% in
Q4, Q3, Q2, and Q1, respectively). Similarly, an increasing
estimated blood loss also led to a stepwise increase in risk of
SSI (7.4% vs 5.9% vs 3.7% vs 2.5% in groups 4, 3, 2, and 1,
respectively). Use of chlorhexidine, with or without
alcohol, was protective against SSI (3.5% vs 5.6%). In the
VQI cohort, gender and diabetes were not statistically
signiﬁcant risk factors for SSI.
Multivariable analysis of process factors. Table III
demonstrates variables that were independently associated
with increased odds of SSI, including ABI <0.35 (OR,
1.54; 95% conﬁdence interval [CI], 1.03-2.30; P < .04),
transfusion >2 units (OR, 3.30; 95% CI, 2.17-5.02;
P < .001), and procedure time $220 minutes (OR, 2.11;
95% CI, 1.05-4.23; P < .04). Chlorhexidine, with or
without alcohol, was protective against SSI (OR, 0.53; 95%
CI, 0.35-0.79; P ¼ .002) compared with iodine, with or
without alcohol. Performance statistics for the multivari-
able model were C statistic ¼ 71%, pseudo r2 ¼ 7.0%, Brier
score ¼ 0.039, and Hosmer-Lemeshow test: c2 ¼ 2.6;
degrees of freedom ¼ 9; associated P value (Pr >
c2) ¼ .98.
For further validation, additional stratiﬁed analyses
were performed to examine the SSI rates in different
Fig 1. Predicted surgical site infection (SSI) rate based on modi-
ﬁable risk factors. SD, Standard deviation.
Table III. Multivariable analysis of the cohort
Variable OR 95% CI P
ABI <0.35 1.54 1.03-2.30 <.04
Procedure time >220 minutes 2.11 1.05-4.23 <.04
Transfusion >2 units pRBCs 3.30 2.17-5.02 <.001
Chlorhexidine w/wo alcohol prep 0.53 0.35-0.79 .002
ABI, Ankle-brachial index; CI, conﬁdence interval; OR, odds ratio; pRBCs,
packed red blood cells; w/wo, with or without.
JOURNAL OF VASCULAR SURGERY
1242 Kalish et al November 2014subgroups, based on the presence or absence of tissue loss.
Among LEB procedures performed in the setting of tissue
loss, chlorhexidine use was also protective (OR, 0.47; 95%
CI, 0.26-0.85; P ¼ .012), and ABI <0.35 was still associ-
ated with higher odds of SSI (OR, 1.82; 95% CI, 1.01-
3.26; P ¼ .045); however, procedure time and transfusion
were no longer signiﬁcant. In procedures done in the
absence of tissue loss, only transfusion >2 units (OR,
3.66; 95% CI, 2.26-5.93; P < .001) and procedure time
>220 minutes (OR, 2.02; 95% CI, 1.02-3.97; P ¼ .042)
were associated with higher odds of infection, whereas
chlorhexidine use did not reach statistical signiﬁcance
(OR, 0.73; 95% CI, 0.47-1.15; P ¼ .179).
Further analysis examined the risk of SSI depending on
the presence of any one, two, or all three of the modiﬁable
risk factors (transfusion, procedure time, chlorhexidine).
Results showed an increase in SSI risk as the number of
modiﬁable risk factors increased (Fig 1). Predicted SSI rates
were 3.2% 6 2.1% for one risk factor, 4.8% 6 3.6% for two
risk factors, and 10.2% 6 1.0% for all three risk factors.
SSI variation by center. There was signiﬁcant varia-
tion by center for each of the modiﬁable risk factors. Chlor-
hexidine usage varied from 0% to 100% (median, 95%;
IQR, 46%-100%), procedure time >220 minutes varied
from 5% to 100% (median, 50%; IQR, 28%-66%), and
transfusion >2 units pRBCs varied from 0% to 40% (me-
dian, 8.5%; IQR, 2.0%-20%). Across VQI hospitals, 63 of
91 centers contributed >20 LEB procedures during the
study period. Observed SSI rates within these 63 VQI cen-
ters ranged from 0% to 30%, whereas expected SSI rates
adjusted by the four signiﬁcant predictors from multivariate
analysis ranged from 0% to 7.2% (median SSI rate, 2.7%;
IQR, 1.0%-5.0%). Fig 2 demonstrates the observed vs ex-
pected SSI rates for centers that contributed at least 20
LEB procedures. A signiﬁcantly higher than expected SSI
rate was seen in six centers after adjusting for ABI <0.35,
transfusion, chlorhexidine skin preparation, and procedure
time.
DISCUSSION
Summary. SSI is a major source of morbidity after
infrainguinal LEB.1 In this study, we report that
observed SSI rates in patients undergoing LEB can range
between 0% and 30%, and that four variables appear to
independently inﬂuence the development of SSI. These
factors are a preoperative ABI <0.35, a perioperative
transfusion >2 units pRBCs, and prolonged operativeduration (>220 minutes). Importantly, use of chlorhexi-
dine as intraoperative skin preparation was protective
against SSI. Unlike most similar studies to date, our
evaluation of the VQI cohort identiﬁed modiﬁable risk
factors that could potentially be altered through quality
improvement initiatives to lower SSI rates.
Epidemiology of SSI. The etiology of SSI is multifac-
torial, and most of the previously published risk factors
are not modiﬁable. Many investigators have noted the asso-
ciation between SSI and the preoperative variables of
female gender,6,8 critical limb ischemia,6 obesity,6,9 and
dialysis.10 Although this study identiﬁed the same factors
on univariate analysis, their statistical signiﬁcance was not
upheld in the multivariable models, where modiﬁable
predictors became more important than the patient-related
factors.
Perioperative variables. Previous studies also evalu-
ated perioperative risk factors for the development of SSI.
In their study of 8799 patients from the NSQIP database,
O’Keeffe et al13 found there was a higher risk of 30-day
morbidity, including infectious complications, after intra-
operative transfusion in patients undergoing lower
extremity revascularization. Wound complications,
including superﬁcial, deep, and organ space SSI, and also
wound dehiscence, were higher with transfusion. How-
ever, after adjustment for transfusion propensity and
patient and procedural risks, wound occurrences were no
longer signiﬁcantly increased as a result of transfusion. In
their model, they accounted for potential cofounders by
incorporating preoperative hematocrit, procedure type,
and duration of operation; however, database limitations
only permitted analysis of intraoperative, and not post-
operative, transfusions. In the VQI database, analysis of
blood transfusion included intraoperative and post-
operative transfusions, and the VQI includes every bypass
performed during the time period, as opposed to the
sampling that is taken for NSQIP evaluations.
Fig 2. The observed (diamond) and expected (solid line) surgical site infection (SSI) rate after lower extremity bypass
(LEB) by Vascular Quality Initiative (VQI) center. ABI, Ankle-brachial index; AUC, area under the curve.
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a correlation between blood transfusions and increased
postoperative infections,17 including sternal wound in-
fections,18 nosocomial pneumonia,18 and mediastinitis.19
Dose-dependent associations of transfusions with infections
have been identiﬁed in cardiac surgery18,20 and vascular sur-
gery,12 possibly due to the suppressive effect of transfusionon
the immune system. Current hypotheses suggest that blood
transfusions lead to immunomodulation21 in addition to
downregulation of macrophage and T-cell immunity.22 As
a result, thepresumedbeneﬁts of blood replacement for acute
blood loss anemia in the perioperative period must be
weighed against the risk of infectious complications of SSI,
among others.
A recent VSGNE analysis detailed the 30-day and
midterm outcomes of SSI within the LEB cohort after
blood transfusion.12 This study included 1880 consecutive
infrainguinal LEBs performed for critical limb ischemia
only, and perioperative transfusion was categorized as
0 units (1532 LEB patients [81.5%]), 1 to 2 units (248
[13.2%]), and $3 units (100 [5.3%]). Cohort frequency
group matching was used to compare the three groups of
patients after matching for age, coronary artery disease, dia-
betes, urgency, and indication for revascularization, and
this method identiﬁed similar ﬁndings as the examination
of the overall cohort. Multivariable analysis showed trans-
fusion was independently associated with increased periop-
erative SSI (1-2 units vs 0 units: OR, 2.1; P ¼ .004; $3
units vs 0 units: OR, 3.8; P < .001). Adjustments for base-
line hemoglobin levels similarly did not change the results.
The advantage of this nationwide VQI study over the
regional VSGNE study is the inclusion of more patientsfrom more institutions, which eliminates the potential in-
ﬂuence of region on outcomes while simultaneously
keeping the collected data variables and methodologies
the same.
The association of operative duration and SSI has
recently been examined as well. Using the NSQIP data-
base, Tan et al14 evaluated 2644 primary femoral-
popliteal bypasses with autologous vein and examined SSI
based on four quartiles of procedure time (Q1:
#149 minutes, Q2: 150-192, Q3: 193-248, Q4: $249).
Patients with longer operative durations had higher body
mass index, greater frequency of critical limb ischemia,
lower preoperative hematocrit, more intraoperative trans-
fusion, and were more likely to have an attending operating
with the participation of a trainee. Longer duration of sur-
gery was associated with increased perioperative SSI
(Q1: 6.3%, Q2: 9.0%, Q3: 10.1%, Q4: 13.9%; P < .001).
Operative duration of $260 minutes increased the risk of
SSI by 50% compared with an operative time of 150 mi-
nutes. Unmeasured patient-speciﬁc and hospital-speciﬁc
factors likely confounded the evaluation of infections in
the less detailed NSQIP database; our current study of
the VQI registry, with its more granular data collection,
does not suffer from this type of confounding.
Other studies have similarly shown higher rates of SSI
with longer operative duration. Culver et al23 found that
the cutoff of 3 hours was the marker for increased SSI dur-
ing vascular surgical procedures, whereas Cruse et al24
noted a doubling of the SSI rate with every hour spent in
the operating room. In their review of 23,649 surgical
wounds, infection rates were 4.4% after operations lasting
between 2 and 3 hours, and 2.8% when surgery time was
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et al25 demonstrated that hospitals that were high outliers
for SSI also had substantially longer operation times.
Although numerous confounding variables can result in
prolonged operative duration, including surgeon-speciﬁc,
system-speciﬁc, and patient-speciﬁc factors, it appears that
attempts to shorten the duration of time spent in the oper-
ating room may result in improved patient outcomes and
decreased hospital resource utilization.
Interventions to prevent SSI. Extensive research has
been directed to reduce SSI in the preoperative setting
immediately before the skin incision.26,27 Optimal preop-
erative antibiotic regimens have been formulated and
evaluated,28-30 and preoperative antibiotics were used 94%
of the time in the VQI, thus demonstrating excellent
compliance across VQI centers with established guidelines.
In addition, preoperative showering/bathing with different
antiseptic solutions has been reviewed,31 and different
methods of hair removal have been evaluated.32 Recently,
chlorhexidine-alcohol has been compared with povidone-
iodine in different surgical specialties, with results favor-
ing chlorhexidine-alcohol.27,33 In the case of central
venous catheters, the use of chlorhexidine gluconate has
reduced infections by 49%.34 In fact, this speciﬁc measure
has been so effective that the Centers for Disease Control
and Prevention (CDC) have incorporated chlorhexidine
into their published guidelines for the prevention of
intravascular catheter-related infections.35
Clean-contaminated operations are expected to have
higher rates of infection than clean operations, and the
use of chlorhexidine has been protective across many
different surgical operations and varying specialties.
Darouiche et al27 demonstrated this effect in a six-center
randomized trial including 849 patients. The SSI rate was
reduced from 16.1% to 9.5% with the use of
chlorhexidine-alcohol for skin antisepsis. According to their
calculations, 17 patients must be prepared with
chlorhexidine-alcohol to avoid one SSI. Levin et al33 found
a similar effect: SSI in gynecologic surgical patients was
reduced from 14.6% to 4.5% with the use of chlorhexi-
dine-alcohol.33
The superior protection against SSI provided by chlor-
hexidine may be related to its more rapid onset of action,
its persistent activity despite exposure to bodily ﬂuids,
and its residual and more prolonged efﬁcacy.36 Gyneco-
logic microbiologic studies have also demonstrated that
chlorhexidine gluconate-based solutions are more effective
than povidone-iodine-based preparations in reducing bac-
terial concentration in the operative ﬁeld for vaginal hyster-
ectomy.37 Similarly, orthopedic studies have corroborated
that 2% chlorhexidine gluconate with 70% alcohol is
more effective than 0.7% iodine and 74% isopropyl alcohol
in eliminating bacteria from the forefoot operative ﬁeld.38
This study grouped LEB procedures performed for all
indications (claudication, critical limb ischemia, and acute
ischemia) and similarly grouped prosthetic and vein by-
passes. Although at face value there may appear to be dif-
ferences within these groups that would warrant theirseparation (increased SSI in tissue loss, acute ischemia,
and use of vein grafts), multivariable analysis did not
conﬁrm any differences that would lead to confounding
by such grouping. In addition, although stratifying by tis-
sue loss caused some of the modiﬁable risk factors to lose
their statistical signiﬁcance, the overall results and trends
were still similar within these smaller data sets.
This VQI study identiﬁed improvement opportunities
directly pertinent to providers that are not available in
typical administrative data sets. Unlike previous studies,
this VQI study also revealed that modiﬁable process mea-
sures (transfusion rate, procedure time, and type of skin
preparation) may be more important than patient factors
in reducing SSI rates. As a result, the information gained
from this analysis was shared with the SVS Patient Safety
Organization Arterial Quality Committee and the individ-
ual VQI centers to foster quality improvement efforts. Each
center-speciﬁc report contained observed vs expected SSI
rates, the rates of the three modiﬁable process measures,
and the resources to assist with SSI prevention.
Study limitations. This study has several limitations.
First, the VQI is a prospectively collected database, and
queries of the data represent index hospitalization observa-
tions only rather than a randomized controlled trial. This
partly explains the lower identiﬁed SSI rates within the
VQI compared with the BASIL and PREVENT III clinical
trials, which tracked infection results for 30 days. VQI SSI
rates are also lower due to the inclusion of bypass proce-
dures performed for multiple indications, including claudi-
cation, instead of solely for critical limb ischemia as in the
above trials.
Second, the deﬁnitions of SSI within the VQI were
more liberal than those deﬁnitions used by the CDC.
The CDC deﬁnes a superﬁcial incisional SSI as an infection
that occurs #30 days after an operation, involves only skin
or subcutaneous tissue, and involves at least one of the
following: purulent drainage, organisms isolated from an
aseptically obtained culture of ﬂuid, certain signs or symp-
toms of infection coupled with the deliberate opening of
the incision by the surgeon (unless cultures are negative),
and diagnosis of SSI by the surgeon.39 Similarly, the VQI
data represent in-hospital SSI rates only, which are ex-
pected to be lower than 30-day SSI rates. However, the
identiﬁed predictors are presumed to be similar for SSI
after discharge.
Third, the database was missing information for certain
demographic variables and in-hospital data points, possibly
due to inaccurate recording but also due to possible prac-
tice patterns. ABI was not recorded in 31% of LEB
patients, and transfusion was not recorded in 6%. Similar
imprecision was found for the newer variables of skin prep-
aration (10% of data missing after this variable was added in
July 2010) and procedure time (5% of data missing after
this variable was added in July 2010). Missing data were
not imputed, and procedures that were missing data were
not entered into the ﬁnal models.
Fourth, because of the nature of the database, 89% of
the patients were Caucasian, and the generalizability of
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Last, the VQI cannot determine the exact cause and
timing of blood transfusion in relation to the index LEB
operation or the transfusion threshold or triggers within
participating centers, where practices likely vary across the
VQI. Similarly, there is likely a variation within centers of
patient-speciﬁc and system-speciﬁc factors that lead to
shorter or longer procedure times, irrespective of the
surgeon-speciﬁc factors. Collinearity was not examined
speciﬁcally in terms of possible interactions between bypass
target (popliteal vs distal target) and procedure time and
will need to be examined further as the number of proce-
dures in the VQI increases; however, although distal tar-
gets had a higher incidence of SSI on univariate analysis,
it did not maintain signiﬁcance in the multivariable model.
Overall, however, this study reﬂects a true representa-
tion of actual practice in community and academic settings,
in all regions throughout the country, and the results from
this study can be used by the centers to evaluate their inter-
nal practice patterns and triggers for transfusion. In addi-
tion, although procedure duration and transfusion may
appear to be surrogates for more complex procedures
and thus could theoretically explain the increased rates of
SSI, other similar surrogates (distal target, obesity, use of
vein graft conduits) did not reach signiﬁcance in multivari-
able analysis.
Even with its limitations, the utility of the VQI data-
base has been bolstered through numerous other studies
that have been published from the regional VSGNE data-
base.12,40 The SVS VQI is uniquely organized as a distrib-
uted network of regional quality groups to facilitate local
translation of registry data into practice change while main-
taining the power of a national registry.15,41 This study is
the ﬁrst VQI initiative to be reported, and it capitalizes
on the experiences from the regional registry evaluations
for the best methods to examine and analyze the data.
This study is also the ﬁrst initiative in the ﬁeld of vascular
surgery to be undertaken in the hopes of quality improve-
ment and represents an important stride in efforts to
improve quality, safety, effectiveness, and cost of vascular
health care.
CONCLUSIONS
In-hospital SSI after LEB varies substantially across
VQI hospitals. Three modiﬁable processes of cared
transfusion rate, procedure time, and type of skin
preparationdwere identiﬁed, and center-speciﬁc results
were shared with individual hospitals to facilitate the poten-
tial reduction of SSI rates. This study demonstrates the
importance of the SVS VQI detailed shared clinical registry
to expand upon the successes of regional quality improve-
ment initiatives and creates a framework for future en-
deavors to establish additional evidence-based “best
practices in vascular surgery.”
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